Myths, Read Against the EvidenceArticle 21 of 27

Do GLP-1 peptides cause blindness?

DIABETIC RETINOPATHY

For people who already have retinopathy, rapid improvements in blood sugar can transiently worsen the eye disease. That's a property of how fast blood sugar changes, not specific to these peptides, and the label for some products acknowledges it.

THE NAION SIGNAL

The second topic is a rare optic-nerve event called non-arteritic anterior ischemic optic neuropathy (NAION), a sudden vision loss tied to changes in blood flow to the optic nerve.

A 2024 eye-disease study at a major center found the rate was about 4 times higher in patients on semaglutide than in matched comparison patients. A much larger 2025 study covering about 483,000 patient pairs confirmed a signal but at a smaller size: about 1.85 times higher. Both absolute rates are low.

What this means

The popular framing "Ozempic makes you go blind" overstates the magnitude.

The signal is real but rare. The literature treats this as something to watch, not panic about.

← Previous

Do GLP-1 peptides affect birth control?

Do people regain the weight when they stop?

Related myths

Do GLP-1 peptides cause pancreatitis?

Acute pancreatitis is a labeled warning. The absolute rate in trials is low. The symptom pattern is severe persistent abdominal pain.

Do GLP-1 peptides cause gallbladder problems?

Yes. And so does fast weight loss itself. This is a real safety topic.

Do GLP-1 peptides cause hair loss?

Yes, some people lose more hair on these peptides. Not many. And the hair grows back.

Keep building trust

Move from the science to the proof, source, and practical questions.

Science next

What is GLP-1?

Keep the explanation moving with the next evidence-led Science article.

Keep learning

Science next

Are all peptide sources the same? COAs, testing, and traceability

Keep the explanation moving with the next evidence-led Science article.

Keep learning

Science next

Does a certificate of analysis prove a peptide is trustworthy?

Keep the explanation moving with the next evidence-led Science article.

Keep learning

Practical questions

FAQ

Use the FAQ for logistics, safety boundaries, and common buyer questions.

Read the FAQ

References1 sources

See source line · 2026
Hathaway et al. 2024, *JAMA Ophthalmology* (PMID 38958939). Tesfaye et al. 2025, *Diabetes, Obesity and Metabolism* (PMID 41104517).
Source line — see article body
PMID 38958939

Disclaimer. This article is for educational purposes only and does not constitute medical advice. Peptide signals and their therapeutic applications are complex and context-dependent.